C S Portlock

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy
    C S Portlock
    Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Ann Oncol 19:254-8. 2008
  2. ncbi request reprint Anti-angiogenesis and diffuse large B-cell lymphoma: a new treatment opportunity?
    C Portlock
    Department of Medicine, Memorial Sloan Kettering, Cancer Center, New York, NY 10021, USA
    Leuk Lymphoma 47:961-2. 2006
  3. ncbi request reprint Review
    Carol S Portlock
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Adv Hematol Oncol 2:820. 2004
  4. ncbi request reprint The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide
    C S Portlock
    Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 15:1495-503. 2004
  5. ncbi request reprint Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease
    Carol S Portlock
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
    Br J Haematol 125:701-8. 2004
  6. doi request reprint Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience
    S M Edwards-Bennett
    Lymphoma Disease Management Team and Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Oncol 21:574-81. 2010
  7. ncbi request reprint Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma
    C H Moskowitz
    Lymphoma and Hematology Services, Department of Medicine, and Departments of Radiotherapy, Pathology, and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 17:3776-85. 1999
  8. ncbi request reprint Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma
    C H Moskowitz
    Hematology Service, New York, NY, USA
    Ann Oncol 18:1842-50. 2007
  9. pmc Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma
    R Schaffel
    Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Oncol 21:133-9. 2010
  10. ncbi request reprint Establishment of a human cell line (SKI-DLCL-1) with a t(1;14)(q21;q32) translocation from the ascites of a patient with diffuse large cell lymphoma
    A Goy
    Department of Medicine, Memorial Hospital, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Leuk Lymphoma 40:419-23. 2001

Collaborators

Detail Information

Publications26

  1. ncbi request reprint Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy
    C S Portlock
    Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Ann Oncol 19:254-8. 2008
    ..pylori, hepatitis C and Borrelia serologies, Borrelia and Chlamydia fixed tissue PCR, Chlamydia peripheral blood mononuclear cell PCR and hydrogen breath test for small bowel bacterial overgrowth (SBBO) were obtained...
  2. ncbi request reprint Anti-angiogenesis and diffuse large B-cell lymphoma: a new treatment opportunity?
    C Portlock
    Department of Medicine, Memorial Sloan Kettering, Cancer Center, New York, NY 10021, USA
    Leuk Lymphoma 47:961-2. 2006
  3. ncbi request reprint Review
    Carol S Portlock
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Adv Hematol Oncol 2:820. 2004
  4. ncbi request reprint The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide
    C S Portlock
    Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 15:1495-503. 2004
    ..The NHL-15 protocol is a novel, dose-intense, dose-dense, sequential chemotherapy program developed to improve outcome in advanced, aggressive non-Hodgkin's lymphomas...
  5. ncbi request reprint Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease
    Carol S Portlock
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
    Br J Haematol 125:701-8. 2004
    ..CD20(+) cHD is a poor prognostic factor for TTF and OS. All cHD cases should be immunophenotyped for CD20. A large prospective trial is needed to confirm these findings...
  6. doi request reprint Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience
    S M Edwards-Bennett
    Lymphoma Disease Management Team and Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Oncol 21:574-81. 2010
    ..We retrospectively examined whether treatment at our institution carefully following Stanford V guidelines would confirm the original Stanford outcome data...
  7. ncbi request reprint Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma
    C H Moskowitz
    Lymphoma and Hematology Services, Department of Medicine, and Departments of Radiotherapy, Pathology, and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 17:3776-85. 1999
    ....
  8. ncbi request reprint Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma
    C H Moskowitz
    Hematology Service, New York, NY, USA
    Ann Oncol 18:1842-50. 2007
    ..We incorporated a thrombopoietic agent into the ICE chemotherapy program to potentially: decrease platelet associated toxicities, augment stem cell collection and maintain dose intensity...
  9. pmc Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma
    R Schaffel
    Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Oncol 21:133-9. 2010
    ..The mantle cell international prognostic index (MIPI) has been reported to have prognostic importance. In this study, we determined the prognostic value of the PI as determined by quantitative image analysis in MCL...
  10. ncbi request reprint Establishment of a human cell line (SKI-DLCL-1) with a t(1;14)(q21;q32) translocation from the ascites of a patient with diffuse large cell lymphoma
    A Goy
    Department of Medicine, Memorial Hospital, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Leuk Lymphoma 40:419-23. 2001
    ..In addition, the BCL9 gene was not over-expressed in SKI-DLCL-1 cell line. The identification of a new locus at 1q21 will help clarify the pathogenesis of B-cell malignancies with a translocation involving this locus...
  11. ncbi request reprint CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas
    Dorothy Pan
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Leuk Lymphoma 44:967-71. 2003
    ..No myelodysplasia or acute leukemia has been seen to date. With no obvious improvement in CR and with greater hematologic toxicity than CHOP, CHOP-HC is not recommended for treatment of indolent non-Hodgkin's lymphomas...
  12. doi request reprint Long-term cardiac and pulmonary complications of cancer therapy
    Joachim Yahalom
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 22:305-18, vii. 2008
    ..Potential preventive measures for high-risk patients are of increasing interest but remain experimental...
  13. ncbi request reprint Primary follicular lymphoma of the gastrointestinal tract: a clinical and pathologic study of 26 cases
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, U S A
    Am J Surg Pathol 26:216-24. 2002
    ..The estimated 5-year disease-free survival was 62%, and median disease-free survival was 69 months. The estimated 5-year relapse-free survival was 54%, and the median relapse-free survival was 63 months...
  14. ncbi request reprint The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin disease
    Scott A Laurie
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 95:119-26. 2002
    ..The objective of this study was to document the natural history of second lung carcinomas, common second tumors that arise in survivors of Hodgkin disease (HD)...
  15. ncbi request reprint Stanford V and radiotherapy for Hodgkin's disease
    Carol S Portlock
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 4:413. 2002
  16. ncbi request reprint CHOP and rituximab in elderly patients
    Carol S Portlock
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 4:414. 2002
  17. ncbi request reprint Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999
    Paul A Hamlin
    Medicine Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 130:691-9. 2005
    ....
  18. ncbi request reprint Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease
    David J Straus
    Memorial Sloan Kettering Cancer Center, SR 441B Box 406, 1275 York Ave, New York, NY 10021, USA
    Blood 104:3483-9. 2004
    ..Although significant differences were not seen, it is possible that a benefit in outcome of less than 20% for CMT might be seen in a larger trial...
  19. ncbi request reprint Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation
    Dorothy Pan
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer J 8:371-6. 2002
    ..In these cases, there is limited salvageability with the use of conventional therapy. The purpose of this retrospective analysis was to evaluate single-agent rituximab as treatment for aggressive non-Hodgkin's lymphomas in these cases...
  20. ncbi request reprint Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
    Paul A Hamlin
    Lymphoma and Hematology Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Box 350, 1275 York Ave, New York, NY, 10021
    Blood 102:1989-96. 2003
    ..This powerful prognostic instrument should be used to evaluate new treatment approaches and to compare results of different regimens...
  21. ncbi request reprint Nemaline myopathy: a possible late complication of Hodgkin's disease therapy
    Carol S Portlock
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hum Pathol 34:816-8. 2003
    ..We are unaware of previous reports documenting such a phenomenon, which suggests that nemaline myopathy may evolve as a radiation-related disorder...
  22. pmc The diminishing role of surgery in the treatment of gastric lymphoma
    Sam S Yoon
    Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA
    Ann Surg 240:28-37. 2004
    ..This article reviews the pathogenesis, diagnosis, and treatment of patients with primary gastric lymphoma, with special attention to the changing role of surgery...
  23. ncbi request reprint T-cell rich B-cell lymphoma: clinical distinctiveness and response to treatment in 45 patients
    Jonathan A Ripp
    Yale University School of Medicine, New Haven, CT USA
    Leuk Lymphoma 43:1573-80. 2002
    ..Initial Hodgkin's disease-directed (HD-directed) chemotherapy should be avoided, although salvage transplantation may result in prolonged survival...
  24. ncbi request reprint Nodular lymphocyte predominant Hodgkin's disease
    Carol S Portlock
    Memorial Sloan Kettering Cancer Center New York, New York 10021, USA
    Cancer Treat Res 131:353-62. 2006
  25. ncbi request reprint Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?
    Carol S Portlock
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 47:1260-4. 2006
    ..9%). PegIFN plus rituximab as delivered in this study is not recommended. PegIFN does not appear to upregulate CD20 expression in peripheral lymph node tumor cells...
  26. ncbi request reprint Unusual abdominal tumors, case 2. Localized amyloid associated with gastric adenocarcinoma
    David Z Chang
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 22:1520-2. 2004